The present and future of measurable residual disease testing in acute myeloid leukemia

Considerable progress has been made in the past several years in the scientific understanding of, and available treatments for, acute myeloid leukemia (AML). Achievement of a conventional remission, evaluated cytomorphologically via small bone marrow samples, is a necessary but not sufficient step t...

Descripción completa

Detalles Bibliográficos
Autores principales: Blachly, James S., Walter, Roland B., Hourigan, Christopher S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Review Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713561/
https://www.ncbi.nlm.nih.gov/pubmed/36453518
http://dx.doi.org/10.3324/haematol.2022.282034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713561/
https://www.ncbi.nlm.nih.gov/pubmed/36453518
http://dx.doi.org/10.3324/haematol.2022.282034

Ejemplares similares